Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.41 |
| ▸ | FPR3 | P25089 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11919050 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2CCR8BCHEGNAI3GNAO1 | |
| SCHEMBL10108953 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2CCR8GNAI3GNAO1GNAI1 | |
| SCHEMBL19021853 | 0.85 | GNAI3 (0.55) | SMN1; SMN2CCR8BCHEGNAI3GNAO1 | |
| SCHEMBL17285633 | 0.85 | GNAI3 (0.55) | SMN1; SMN2GNAI3GNAO1GNAI1KDM4E | |
| SCHEMBL8212540 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2BCHEGNAI3GNAO1GNAI1 | |
| SCHEMBL12719407 | 0.82 | BCHE (0.49) | SMN1; SMN2CCR8BCHEGNAI3GNAO1 | |
| SCHEMBL13061270 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2GNAI3GNAO1GNAI1EPHX2 | |
| SCHEMBL19009046 | 0.82 | KDM4E (0.56) | SMN1; SMN2CCR8BCHEGNAI3GNAO1 | |
| SCHEMBL1678458 | 0.81 | — | — | |
| SCHEMBL8282846 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2GNAI3GNAO1GNAI1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| WO-2023065014-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2023-04-27 | — | — | WO | disclosed |
| EP-3889145-A1 | 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-10544122-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-01-28 | — | — | US | disclosed |
| US-20190330183-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SMN1; SMN2 1984/4885CCR8 37/4885BCHE 4796/4885 |
| US-20190330183-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SMN1; SMN2 1984/4885CCR8 37/4885BCHE 4796/4885 |
| US-10544122-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | SMN1; SMN2 1984/4885CCR8 37/4885BCHE 4796/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SMN1; SMN2 2610/4885CCR8 28/4885BCHE 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.